Alzheimer's Association: The Tau Pipeline Enabling Program (T-PEP) - LOI

Proposals responding to this program may focus on the toxicity of tau directly and/or they may target their studies on potential neurobiological mechanisms that promote or synergize tau formation or toxicity, e.g. calcium dyshomeostatis, mitochondrial dysfunction, neuroinflammation, microtubule stability (or instability) and function, axon transport, synapse dysfunction/loss, and other tau-related mechanisms. Applications addressing related mechanisms must include the rationale that it will prevent, reduce, remove or otherwise mitigate the toxic effects of tau build-up. Funds awarded under this program may be used for one or more steps in the drug discovery pipeline, including but not limited to i) lead discovery and optimization, ii) target validation and iii) IND-enabling studies, including cGMP scale-up/manufacture and animal efficacy studies.

Funding: up to $750K for 2 years. Please contact Research Authority if planning to submit.

www.alz.org/research/for_researchers/grants/types-of-grants